EUVIMEDΑνακαλύψτε το EUVIMED
Fallbericht

Therapeutic plasmapheresis in idiopathic membranous nephropathy anti‐PLA2R‐related: A case series

Dario Musone iD, Valentina Nicosia, Riccardo D'Alessandro, Marco Andrietti, Paolo Francesco Steri, Carolina Ruosi, Sofia Giuliana, Claudia Elefante, Pina Cuccurullo, Antonio Treglia

Journal of Clinical Apheresis · 2024

DOI: 10.1002/jca.22134 ↗

At a glance

Fallbericht in Journal of Clinical Apheresis, 2024. Written by Dario Musone and 9 co-authors. Institution: UOC Nefrologia e Dialisi, Formia, Italy. Major MEDLINE topics: Plasmapheresis, Glomerulonephritis, Membranous, Receptors, Phospholipase A2, Rituximab. Cited 3 times so far (Crossref); 29 references.

ΠερίληψηSubjectsΒιβλιογραφικά στοιχείαCiteRelated studies

Abstract (original language)

Membranous nephropathy is the most common cause of nephrotic syndrome (NS) in non‐diabetic adults; in 80% of patients it is idiopathic (PMN). PMN has an autoimmune pathogenesis, 70%‐85% of patients have increased titer of antibodies to the podocyte membrane antigen PLA2R. The etiological, prognostic and predictive role of the Ab anti‐PLA2R is demonstrated. Standard therapy consists in anti‐CD20 monoclonal antibody rituximab (RTX) combined with steroids or immunosuppressants according to the risk of progressive loss of kidney function. The immunosuppressive therapies are potentially associated to severe adverse events that lead to protocol suspension. Given their pivotal pathogenetic role, serum clearance of anti‐PLA2R with plasmapheresis could have a beneficial impact on NS, particularly in patients not requiring or tolerating standard therapies. In this series, we present three cases of PMN anti‐PLA2R related treated with a RTX plus plasmapheresis approach and demonstrate its overall effective role on anti‐PLA2R titer and clinical outcomes.

Subjects

MeSH terms (MEDLINE)

PlasmapheresisGlomerulonephritis, MembranousReceptors, Phospholipase A2RituximabHumansMaleMiddle AgedFemaleAdultAutoantibodiesImmunosuppressive Agents

Author keywords

anti‐PLA2Rmembranous nephropathynephrotic syndromeplasmapheresis

Substances

Receptors, Phospholipase A2RituximabPLA2R1 protein, humanAutoantibodiesImmunosuppressive Agents

Authors and institutions

  • UOC Nefrologia e Dialisi, Formia, Italy.

ORCID profiles: Dario Musone

Cite

APA

Musone, D., Nicosia, V., D'Alessandro, R., Andrietti, M., Steri, P. F., Ruosi, C., Giuliana, S., Elefante, C., Cuccurullo, P., & Treglia, A. (2024). Therapeutic plasmapheresis in idiopathic membranous nephropathy anti‐PLA2R‐related: A case series. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.22134

Vancouver

Musone D, Nicosia V, D'Alessandro R, Andrietti M, Steri PF, Ruosi C, et al. Therapeutic plasmapheresis in idiopathic membranous nephropathy anti‐PLA2R‐related: A case series. Journal of Clinical Apheresis. 2024. doi:10.1002/jca.22134

BibTeX
@article{Musone2024,
  author = {Musone, Dario and Nicosia, Valentina and D'Alessandro, Riccardo and Andrietti, Marco and Steri, Paolo Francesco and Ruosi, Carolina and Giuliana, Sofia and Elefante, Claudia and Cuccurullo, Pina and Treglia, Antonio},
  title = {Therapeutic plasmapheresis in idiopathic membranous nephropathy anti‐PLA2R‐related: A case series},
  journal = {Journal of Clinical Apheresis},
  year = {2024},
  doi = {10.1002/jca.22134}
}
Start for free →